Novavax, Inc. (NASDAQ: NVAX) may show how little key impact news there is, but it is the top mover today in percentage terms seen. At 8:28 AM EST we have seen 75,000 shares trade (versus 6 million average) and the stock is up 6.6% at $3.20. This is on news that it has completed enrollment in Phase IIa studies of seasonal influenza vaccine in older adults. The 52-week range is $0.52 to $7.79.
JON OGG
No comments:
Post a Comment